2 results
Approved WMOPending
To evaluate the efficacy of lebrikizumab compared with placebo in patients not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16
Approved WMORecruiting
To assess the superiority of an IVUS-guided approach versus a qualitative angio-guided approach in patients with complex coronary lesions undergoing PCI.